Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
NCT04146155 on ClinicalTrials.gov · last registry update 2021-07-07
An unusually large phase 4: 200 participants, more than double the 75 typical for the stage. Its estimated completion date, 31 December 2021, has passed with no update to the record. Primary outcome, as filed: Initial and absolute claudication distance. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sponsor type
- Other
- Enrollment
- 200
- Started
- 2020-05-01
- Primary completion
- 2021-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Initial and absolute claudication distance
Conditions studied
Type 2 Diabetes · Peripheral Vascular Disorder Due to Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.